By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Syndax Pharmaceuticals Inc. 

Waltham  Massachusetts    U.S.A.
Phone: 781-839-7301 Fax:


Start Up

Company News
Syndax Pharmaceuticals Inc. And Merck & Co. (MRK) To Collaborate On Immuno-Oncology Study Evaluating Entinostat In Combination With KEYTRUDA (Pembrolizumab) In Lung Cancer And Melanoma 3/31/2015 11:28:27 AM
Syndax Pharmaceuticals Inc. To Participate In Two Upcoming Conferences 3/12/2015 11:06:36 AM
Syndax Pharmaceuticals Inc. To Present At 2015 BIO CEO & Investor Conference 2/5/2015 12:28:45 PM
Syndax Pharmaceuticals Inc. Snags $125 Million Deal With Kyowa Hakko Kirin 1/8/2015 7:34:35 AM
Syndax Pharmaceuticals Inc. Release: Entinostat Improves Treatment Outcomes When Combined With Immune Checkpoint Blockade In Preclinical Tumor Models 7/30/2014 8:25:39 AM
Cancer Biotech Syndax Pharmaceuticals Inc. Sets Terms For $60 Million IPO 6/6/2014 6:58:28 AM
Syndax Pharmaceuticals Inc. Announces Presentation Of Entinostat Data In Two Posters At The 2014 American Society of Clinical Oncology (ASCO) Annual Meeting 5/27/2014 6:24:36 AM
Massachusett's Syndax Pharmaceuticals Inc. Plots $69 Million IPO For Cancer Drug's Stretch Run 3/28/2014 7:05:36 AM
Syndax Pharmaceuticals Inc. Announces National Cancer Institute And FDA Reach Agreement On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Entinostat In Patients With Advanced ER+ Breast Cancer 2/13/2014 11:29:41 AM
Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax Pharmaceuticals Inc. As An Independent Director 2/3/2014 6:39:00 AM